Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Founded and led for 30 years by physician-scientists, our unique ability to consistently translate science into medicine has led to numerous FDA-approved treatments and over sixteen product candidates, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies and ambitious initiatives such as the Regeneron Genetics Center®, one of the largest genetics sequencing efforts in the world.

GENERAL COMPANY INFORMATION
- Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
- More than 7,000 employees in the U.S. and EU
- Current annualized R&D spending in excess of $2 billion; partially supported through research collaborations

LOCATIONS
- Tarrytown, NY: Corporate and Research & Development headquarters
- Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities
- Sleepy Hollow, NY and Basking Ridge, NJ: Satellite offices
- Dublin, Ireland and London, UK: EU business offices

LEADERSHIP TEAM
- Leonard S. Schleifer, MD, PhD
  Founder, President and Chief Executive Officer
- George D. Yancopoulos, MD, PhD
  Founding Scientist, President and Chief Scientific Officer
  + Member, National Academy of Sciences
- P. Roy Vagelos, MD
  Chairman of the Board
  + Former Chief Executive Officer and Chairman of the Board, Merck & Co.
  + Member, National Academy of Sciences

- Board of Directors includes two Nobel Laureates and seven members of the National Academy of Sciences

FDA-APPROVED & MARKETED MEDICINES

ArcaLyst® (rilpivirine) Injection for Subcutaneous Use

DUXIXENT® (dulimumab) Injection 300mg

EYLEA® (afibercept) Injection For Intravitreal Injection

KEVZARA® (sarilumab) injection 150mg / 200mg

Praluent® (alirocumab) Injection For Intravenous Injection

Please see Full Prescribing Information including Boxed WARNING at www.kevzara.com

*U.S. Food and Drug Administration.
LEADERS IN TECHNOLOGY

- **Fully human monoclonal antibodies**: Regeneron has developed a suite of patented technologies (VelociSuite®), including VelociGene®, VelocImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

- **Fusion proteins**: Our novel and patented “Trap” fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

- **Regeneron Genetics Center**: A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.